Stifel Reiterates Buy Rating on MBX Biosciences Inc (MBX), eyes MBX-4291 GLP Ph.1/2a trial results in Q4
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $50.00 price target on MBX Biosciences Inc (NASDAQ: MBX)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
